Vitamin D and non-Hodgkin lymphomas, trends from an Italian monocentric study
Massimiliano Postorino(University of Rome Tor Vergata), Maria Cantonetti(University of Rome Tor Vergata), Stefan Hohaus, Andrea Perrone(Università Cattolica del Sacro Cuore), Giovanni Del Poeta(University of Rome Tor Vergata), Renato Massoud(University of Rome Tor Vergata), Giorgio VACROS(University of Rome Tor Vergata), Michele La Manna(University of Rome Tor Vergata), Luigi Tonino Marsella(University of Rome Tor Vergata), Elisa Meddi(University of Rome Tor Vergata), Jacopo Giammatteo(University of Rome Tor Vergata), Cristiano Tesei(University of Rome Tor Vergata), Luca Guarnera(University of Rome Tor Vergata), Annagiulia Zizzari(University of Rome Tor Vergata), Vito Mario Rapisarda(University of Rome Tor Vergata)
Cited by 2
Related Papers
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
|Journal of Clinical Oncology|2016|754
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
|Clinical Cancer Research|2018|311
Intravesical Electromotive Mitomycin C Versus Passive Transport Mitomycin C for High Risk Superficial Bladder Cancer: A Prospective Randomized Study
|The Journal of Urology|2003|252